Thesis (doctoral)--Lund University, 1998. / Added t.p. with thesis statement inserted. Includes bibliographical references.

Thesis (doctoral)--Lund University, 1998. / Added t.p. with thesis statement inserted. Includes bibliographical references.

Abstract Type XIII collagen belongs to the group of transmembrane collagens. In this thesis the plasma membrane localisation and function of type XIII collagen have been studied using cell biological methods. Type XIII collagen was found to reside in focal adhesions. It appeared in these structures at a very early stage of their assembly and disappeared from them concurrently with focal adhesion proteins talin and vinculin. Insect cells expressing type XIII collagen showed an enhanced adhesion to certain matrix components. These localisation and adhesion data suggested that the function of type XIII collagen is related to cell adhesion. Supporting this, in tissues type XIII collagen was found to localise to cell-matrix and cell-cell adhesion structures. Type XIII collagen was found to be partly present in cholesterol-enriched membrane microdomains. With other membrane proteins this localisation has been shown to be linked to ectodomain shedding. The connection between the membrane microdomain localisation and the ectodomain shedding of type XIII collagen was also characterised, and it was demonstrated that manipulation of the cellular cholesterol level affected the efficiency of the ectodomain shedding. Additionally, insights into intracellular shedding of type XIII collagen in the Golgi apparatus were obtained. The study of type XIII collagen expression in human cancers revealed that it was enhanced especially in the desmoplastic cancer stroma. Since the increased expression of type XIII collagen was detected during the dysplastic stages, type XIII collagen may be involved in the early pathogenesis of cancer. The result indicated that type XIII collagen is involved in the matrix remodelling. In support of this, the cell culture experiments showed that the soluble type XIII collagen ectodomain altered the vitronectin-rich matrix unfavourable for cell adhesion and spreading. This may enhance cancer metastasis. Type XIII collagen expression was also induced in the remodelled stroma of keratoconus and corneal wounds. Data suggested that myofibroblasts were responsible for the increased expression of type XIII collagen in these situations. Therefore both in cancer and in the corneal pathologies studied, type XIII collagen expression was induced by the activated stromal cells.

Mammalian circadian rhythms are controlled by a clock located in the suprachiasmatic nucleus (SCN). The mechanisms through which light phase-shifts the SCN circadian clock are similar to those underlying memory formation and long-term potentiation (LTP). Several secreted proteins, including tissue-type plasminogen activator (tPA), plasminogen, and brain-derived neurotrophic factor (BDNF), have been implicated in this process. These same proteins are important for photic phase-shifts of the SCN circadian clock. Early night glutamate application to SCN containing brain slices resets the circadian clock. Our experiments find that the endogenous tPA inhibitor, plasminogen activator inhibitor 1(PAI-1), blocked these shifts in slices from wildtype mice but not mice lacking its stabilizing protein, vitronectin (VN). Plasmin, but not plasminogen, prevented inhibition by PAI-1. Both plasmin and active BDNF reversed alpha2-antiplasmin inhibition of glutamate-induced shifts. alpha2-Antiplasmin decreased the conversion of inactive to active BDNF in the SCN. Both tPA and BDNF allowed daytime glutamate-induced phase-resetting. Together, these data are the first to demonstrate expression of these proteases in the SCN, their involvement in modulating photic phase-shifts, and their activation of BDNF in the SCN, a potential ‘gating’ mechanism for photic phase-resetting. Using western-blot analyses of SCN tissue maintained in vitro, we find higher tPA, plasmin and mBDNF levels in the SCN at night vs. the day. Also, in vitro glutamate treatment of SCN tissue during early night increases tPA levels to ~2.5 times control levels, while similar treatments during late night and mid-day do not alter tPA expression. Glutamate treatment in the early night does not alter PAI-1, plasmin and BDNF levels. Co-treatment with glutamate and PAI-1 decreases plasmin levels (vs. glutamate treatment alone), while co-treatment with glutamate and alpha2-antiplasmin decreases the amount of pro- and mBDNF in the SCN relative to glutamate treatment alone. We also show that mBDNF levels are significantly lower in tPA knockout mice during both day and night. Together, these results support circadian clock modulation of BDNF and fibrinolytic protein levels in the SCN. They also suggest that glutamate modulates tPA expression in the SCN, while tPA and plasmin modulate BDNF expression.

Plasminogen activator inhibitor-1 (PAI-1), a member of the serine protease inhibitor (serpin) superfamily of proteins, circulates in blood in a complex with vitronectin (VN). These two proteins are also found localized together in the extracellular matrix in many different pathophysiological conditions. Both of these proteins are involved with a number of physiologically important processes. Though PAI-1 is a well-known inhibitor of serine proteases, more emphasis is now geared towards its protease independent functions. VN, on the other hand, is a binding protein that exists in the circulation in a preferred monomeric conformation. However, in the extracellular matrix, VN exists as multimer with altered conformation. Though the exact reason for such conformational alterations and compartmentalization is unknown, there are a number of biomolecules, including PAI-1 that are proposed to cause such alterations. In last few years, sufficient experimental evidence has been gathered to confirm this protease- independent effect of PAI-1 by which it induces multimerization of VN in a concentration-dependent fashion. It has been observed also that PAI-1 remains associated with this multimeric complex for several hours. A major focus of this dissertation work was to extend our understanding of the mechanism of the interaction between these proteins and to explore the physiological relevance of the multimeric complexes formed by their interaction on cellular adhesion and migration. In our study, emphasis has been given to the presence of an appropriate microenvironment so that the role of the multimeric complexes could be investigated in a relevant biological setting. Our findings indicate the importance of the surrounding microenvironment in establishing the specific role of the VN/PAI-1 complex in cell-matrix interactions. In a previous study from our lab, it was found that vitronectin knock-out mice were more resistant to Candida infection compared to wild type C57Bl/6 mice. One of the goals of this dissertation work was to provide a mechanistic explanation for their increased survival of the vitronectin knock-out mice upon Candida infection. Another important aspect of this work was to establish biophysical methods for understanding the structural changes that happen in PAI-1 naturally or due to ligand binding.

Recent observations have demonstrated that Insulin-like Growth Factors (IGFs) are able to form complexes with the extracellular matrix protein Vitronectin (VN). These complexes of VN:IGFBP:IGF-I significantly enhance the proliferation and migration of various cell lines including skin and corneal epithelial cells, as well as primary cells derived from human skin and corneal tissue. These enhanced effects arise from co- activation of the IGF-binding type-1 IGF receptor (IGF-1R) as well as activation of the VN-binding αv-integrins. Further studies suggest that these complexes can replace the requirement for serum in the ex vivo expansion of cells. In order to translate the VN:IGFBP:IGF-I technology into techniques for the improved culture of cells, we have designed, expressed and purified synthetic chimeric molecules, consisting of various domains of VN and mature IGF-I, using a baculovirus based expression system. The recombinant VN:IGF-I (rVN:IGF-I) chimeras were secreted into conditioned media of transfected Sf9 insect cells. Purification of the chimeras was achieved via methods including heparin-sepharose chromatography, Q-sepharose ion-exchange chromatography and Ni2+-NTA affinity chromatography. The rVN:IGF-I chimeras were detectable by Western blot analysis using a poly-clonal anti-VN antibody. Functional characterisation studies indicate that the chimeras promote cellular growth and migration to a similar extent as the VN:IGFBP:IGF-I complexes at 10x and 30x molar ratios. Additionally, function blocking antibodies directed to the IGF-1R and the VN binding αv-integrin were able to abolish this effect indicating that co-activation of these receptors is critical to the migratory effect of the chimeras. A functional chimera may lead to the development of cell culture techniques and methodologies that are devoid of xenogeneic or allogeneic support systems, thus paving the way to approved tissue engineering therapeutics that incorporate ex vivo expanded adult stem and progenitor cells.

It has previously been shown that VN can form complexes with IGF-II or IGF-I in combination with its binding proteins IGFBP-3 or -5. This study aimed to determine the efficacy of using these complexes as a treatment designed to accelerate wound healing, particularly in diabetic ulcers. The primary functions of skin cells in wound healing are attachment, proliferation and migration, thus these functions were assessed in response to these complexes in skin cells derived from patients with diabetic ulcers and from non-diabetic patients. These studies examined responses to the complexes in both skin keratinocyte and fibroblast cells. Furthermore, in order to investigate the mechanisms that underlie the responses observed, I also examined the ability of skin cells to retain these functional responses when the complexes incorporated an IGF-I analogue that does not activate the IGF receptor or when the cells had been pre-incubated with an anti-αv-integrin function blocking antibody. In addition, the ability of the cells to survive and grow when treated with the complexes under conditions mimicking the diabetic wound was assessed using growth assays in which the media contained elevated concentrations of glucose and calcium. I found that cells derived from skin from normal patients showed enhanced proliferation in response to these complexes, whereas only the presence of IGF-I and IGFBP seemed to be important in stimulating the proliferation of cells derived from diabetic patients. I also found that enhanced migration was observed in fibroblasts from diabetic ulcers in response to the complexes but these responses only required the presence of VN in normal cells. Both normal and diabetic keratinocytes showed enhanced migration in response to the complexes and the responses involved the interaction of both IGF-I and VN with their respective cell surface receptors. However the enhanced migration observed in diabetic ulcer derived keratinocytes was approximately half the level seen in normal keratinocytes. Furthermore, I showed that cells derived from skin from normal patients exhibited greater proliferation when treated with complexes in the presence of high concentrations of glucose and calcium ion compared to cells that were not treated with the complexes. Likewise, cells derived from skin surrounding diabetic ulcers were able to grow in media containing high levels of glucose and calcium when treated with VN:IGFBP:IGF-I complexes. In particular diabetic skin derived fibroblasts grown in high calcium media demonstrated enhanced proliferation when treated with the complexes, whereas diabetic keratinocyte cells seemed less affected by these conditions than their normal counterparts were. The findings in this thesis show that VN:IGFBP:IGF-I complexes can elicit enhanced growth and migration in cells derived from skin from both normal and diabetic patients. Further, these responses are maintained in conditions found in the diabetic wound microenvironment, namely in the presence of high glucose and high calcium. Together these findings demonstrate the potential of the VN:IGFBP:IGF complexes as wound healing agents to treat wounds, especially diabetic ulcers. Such delayed healing wounds represent a significant burden to health care systems and are one of the primary conditions that leads to the amputation of limbs. Current treatments do not address the co-ordination of ECM and growth factor action on cells that is here demonstrated to stimulate multiple wound healing related functional effects in skin cells. The data presented here represents important new information that may guide the design of new integrated therapeutics that may enhance the healing of recalcitrant diabetic ulcers.

We defined how blood-derived vitronectin (VTN) rapidly and potently activates leukemia inhibitory factor (LIF) and pro-inflammatory interleukin 6 (IL-6) in vitro and after vascular injury in the brain. Treatment with VTN (but not fibrinogen, fibronectin, laminin-111 or collagen-I) substantially increased LIF and IL-6 within 4 h in C6-astroglioma cells, while VTN-/- mouse plasma was less effective than that from wild-type mice. LIF and IL-6 were induced by intracerebral injection of recombinant human (rh)VTN in mice, but induction seen upon intracerebral hemorrhage was less in VTN-/- mice than in wild-type littermates. In vitro, VTNeffects were inhibited by RGD, αvβ3 and αvβ5 integrin-blocking peptides and antibodies. VTN activated focal adhesion kinase (FAK; also known as PTK2), whereas pharmacological- or siRNA-mediated inhibition of FAK, but not PYK2, reduced the expression of LIF and IL-6 in C6 and endothelial cells and after traumatic cell injury.Dominant-negative FAK (Y397F) reduced the amount of injury-induced LIF and IL-6. Pharmacological inhibition or knockdown of uPAR (also known as PLAUR), which binds VTN, also reduced cytokine expression, possibly through a common target of uPAR and integrins. We propose that VTN leakage into tissues promotes inflammation. Integrin-FAKsignaling is therefore a novel IL-6 and LIF regulation mechanism relevant to the inflammation and stem cell fields.

Die ischämische Herzerkrankung (Angina pectoris, Herzinfarkt), eine führende Todesursache in den Industrienationen, wird hauptsächlich durch Intervention an den Koronararterien mittels Ballondilatation meist in Kombination mit einer Stentimplantation behandelt. Trotz aktueller Verbesserungen im Stentdesing und dem Einsatz von medikamente-freisetzenden Stents kommt es immer noch in etwa 10 – 20 % der Interventionen, in Abhängigkeit des jeweiligen Risikoprofils, zu der Entwicklung einer Restenose. Der pathophysiologische Prozess der Neointimaentwicklung, welche der Restenoseentstehung nach Stentimplantation zu Grunde liegt, ist im Wesentlichen durch einwandernde glatte Gefässmuskelzellen (GMZ) bedingt. Eine zentrale Rolle bei der Zellwanderung nehmen alpha V Integrine ein. Um den Prozess der Restenose zu verhindern, stellen somit diese Rezeptoren und die durch sie ausgelösten Signalkaskaden einen vielversprechenden Angriffspunkt dar. Wir konnten nach Stimulation von GMZ aus Schweinen mit den EZM Proteinen Vitronektin (VN), Fibronektin (FN) und Kollagen (CN) eine verstärkte Tyrosinphosphorylierung (PTyr) v.a. eines etwa 116 kDa grossen Proteins zeigen, das mittels Immunpräzipitation als “focal adhesion kinase” (FAK) identifiziert wurde. VN stellte hierbei den stärksten Stimulus dar. Die erhöhte PTyr zeigte sich am Tyrosinrest 397 von FAK (PTyr-397), der Autophosphorylierungsstelle der Kinase, und deutet damit auf eine durch Proteinstimulation induzierte, erhöhte Aktivität von FAK hin. Die erhöhte PTyr von FAK war nicht zu beobachten, wenn die GMZ ohne spezifische Rezeptor-Ligand Interaktion auf Poly-L-Lysin adhärierten. Die Aktivierung von FAK nach Stimulation mit VN, FN und CN war dabei abhängig von alpha V Integrinen und lies sich durch Zugabe eines kompetetiven alpha V Inhibitors in einer Dosis- abhängigen Weise unterdrücken. Die Inhibition war am deutlichsten nach VN Stimulation zu beobachten. Bei Kultivierung der Zellen mit dem Inhibitor über 7 Tage in einer Konzentration von 1 µM war in der Durchlichtmikroskopie im Vergleich zu kultivierten Zellen ohne Inhibitor keine Veränderung zu erkennen. Bei 10 µM Cilengitide verkleinerte sich der Zelldurchmesser, die Zellen blieben jedoch an der Oberfläche der Zellkulturschalen adhärent. In der IF Mikroskopie zeigte sich nach 30 min eine Abnahme der intrazellulären PTyr und ein Abbau des Aktinzytoskeletts unter Einfluss von 10 µM des Inhibitors auf kultivierte adhärente GMZ. Es gab keinen Hinweis auf Induktion einer Apoptose. Auf VN und CN konnten die zuvor suspendierten GMZ gut adhärieren, während auf einer mit FN beschichteten Oberfläche die Anzahl der angehefteten Zellen im Vergleich zu einer unbeschichteten Oberfläche nicht anstieg. Die Adhäsion der GMZ auf VN konnte der Hemmstoff stark vermindern, während er auf die Adhäsion auf FN und CN keinen Einfluss hatte. Die Inhibition der Aktivierung von FAK durch den alpha V Integrininhibitor korrelierte mit der Reduktion der durch die Proteinen stimulierten Migration (Haptotaxis) der primären GMZ. Der Inhibitor führte bei einer Konzentration von 10 µM bei VN Stimulation zu einer fast vollständigen Inhibition der Haptotaxis, während er nach FN bzw. CN Stimulation die Anzahl der gewanderten Zellen bei dieser Konzentration um etwa 30 % verringerte. Die Migrationsrate wurde mit Hilfe eines modifizierten Boyden-Kammer Migrationsversuchs ermittelt. Unsere Ergebnisse unterstreichen die Schlüsselrolle der alpha V Integrine in der Motilität von GMZ. Sie nehmen Einfluss auf Signalkaskaden, die von FAK abhängig sind und die Haptotaxis zu regulieren scheinen. Diese Ergebnisse machen die alpha V Integrine zu einem vielversprechenden Angriffspunkt, um eine Restenose nach Stentimplantation zu verhindern. Der Einsatz des alpha V Integrininhibitors Cilengitide, der mit einem Medikamente-freisetzenden Stent lokal an dem Ort des pathologischen Geschehens appliziert werden kann, lässt somit eine weitere Reduktion der Restenoserate erhoffen, was in einem nächsten Schritt mittels eines in vivo Modells untersucht werden muss. / Aberrant migration of smooth muscle cells (SMCs) is a key feature of restenosis after ptca. Since extracellular matrix proteins and their receptors of the integrin family play a critical role in this process, it is instrumental to understand their contibution to cell migration of SMCs on the molecular level. Therefor we investigated the role of alpha V- containing integrins expressed by porcine coronary artery smooth muscle cells (pCASMCs) in vitronectin (VN), fibronectin (FN) and collagen (CN) initiated signaling events, cell adhesion and migration. In pCASMCs alpha V containing integrins were localized at focal adhesion sites. Stimulation through VN, FN and CN led to increase in cell migration and adhesion and concomitantly to enhanced tyrosine phosphorylation of focal adhesion kinase. These events were attenuated by a specific alpha V inhibitor in a dose dependent manner. This inhibitor could be used for a drug eluting stent and maybe could provide an approach to prevent restenosis after ptca.

The core of the doctoral thesis "Regulation of signal transduction by leukocyte surface proteins" consists of three publications in international peer-reviewed journals dealing with leukocyte signaling both at the level of individual signaling pathways and in the context of a multicellular organism. Most attention is paid to signaling via the T cell receptor (TCR), which plays a central role in the development and function of T cells and represents a key signaling pathway for proper function of the adaptive component of the immune system. Transmembrane protein tyrosine phosphatase CD148 was considered a negative regulator of TCR signaling through dephosphorylation of LAT and PLCγ1 proteins. This study brings evidence that CD148 is able to modulate signaling also at the level of Lck, both positively and negatively. The net effect of CD148 activity on the TCR signaling is determined by the intracellular biochemical context, notably, the presence of another tyrosine phosphatase CD45. The second project dealt with the characterization of a transmembrane adaptor protein PRR7. This adapter inhibits TCR signaling via down-regulation of the intracellular Lck and cell surface TCR levels. The research concerning the signaling in the environment of a multicellular organism is represented by the analysis of...